Micomicen (Ciclopirox Olamine)

Ciclopirox olamine chelates metal ions inside fungal cells, disrupting enzyme activity required for membrane transport and energy production. This interference hampers the synthesis of essential cellular components, leading to fungal cell death while sparing human cells.

The dosage of Micomicen is determined by the prescribing clinician based on the specific formulation and severity of infection. Patients should follow the healthcare provider’s instructions and not alter the regimen without medical advice.

Safety data for ciclopirox olamine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare professional before using Micomicen.

To order Micomicen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Micomicen (ciclopirox olamine) offers a distinct mechanism by chelating metal ions, differing from azole antifungals that inhibit ergosterol synthesis. This can be advantageous in cases of azole‑resistant Candida, though clinical choice depends on infection severity, patient history and physician judgment.

Store Micomicen at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and excessive heat to maintain product stability and efficacy.

Micomicen is applied intravaginally according to the prescriber’s directions. The product is typically inserted into the vagina using the supplied applicator or as directed, ensuring proper placement for optimal therapeutic effect.

Serious risks, although rare, include severe allergic reactions such as rash, swelling, or anaphylaxis, and extensive ulceration of the vaginal mucosa. Patients should seek immediate medical attention if they experience these symptoms.

Micomicen should not be used by individuals with a known hypersensitivity to ciclopirox olamine or any excipients in the formulation. Additionally, patients with severe immunosuppression should use it only under close medical supervision.